drugset / Trial / NCT06802926

Pilot Trial of Colchicine for Graft Failure in CABG

NCT06802926

Phase 4 Recruiting 100 enrolled Ruijin Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The goal of this pilot trial is to to evaluate the preliminary effect of oral colchicine therapy on graft outcomes in patients underwent primary isolated CABG. The main questions it aims to answer is: 1. Whether the oral colchicine therapy may reduce the failure outcome of grafts after CABG. 2. Whether it is feasible to construct a muticenter powered trial to test the superiority hypothesis. Researchers will compare colchicine to none to see if colchicine works. Participants will 1. Take oral colchicine (0.5mg daily) therapy for 12 months after CABG. 2. Clinical follow-up at Month 1, 6, and 12 after CABG. 3. Protocol-driven CCTA at Week 1 and Month 12 after CABG.

Timeline

Start
2025-12-29
Primary completion
2027-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg Oral

Indications

No indication recorded.